136 related articles for article (PubMed ID: 37390404)
1. Systematic Analyses of the Resistance Potential of Drugs Targeting SARS-CoV-2 Main Protease.
Flynn JM; Huang QYJ; Zvornicanin SN; Schneider-Nachum G; Shaqra AM; Yilmaz NK; Moquin SA; Dovala D; Schiffer CA; Bolon DNA
ACS Infect Dis; 2023 Jul; 9(7):1372-1386. PubMed ID: 37390404
[TBL] [Abstract][Full Text] [Related]
2. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
[TBL] [Abstract][Full Text] [Related]
3. Genetic Surveillance of SARS-CoV-2 M
Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
[TBL] [Abstract][Full Text] [Related]
4. Contributions of Hyperactive Mutations in M
Flynn JM; Zvornicanin SN; Tsepal T; Shaqra AM; Kurt Yilmaz N; Jia W; Moquin S; Dovala D; Schiffer CA; Bolon DNA
ACS Infect Dis; 2024 Apr; 10(4):1174-1184. PubMed ID: 38472113
[TBL] [Abstract][Full Text] [Related]
5. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.
Duan Y; Zhou H; Liu X; Iketani S; Lin M; Zhang X; Bian Q; Wang H; Sun H; Hong SJ; Culbertson B; Mohri H; Luck MI; Zhu Y; Liu X; Lu Y; Yang X; Yang K; Sabo Y; Chavez A; Goff SP; Rao Z; Ho DD; Yang H
Nature; 2023 Oct; 622(7982):376-382. PubMed ID: 37696289
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
[TBL] [Abstract][Full Text] [Related]
8. Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.
Colson P; Delerce J; Pontarotti P; Devaux C; La Scola B; Fantini J; Raoult D
J Med Virol; 2024 Feb; 96(2):e29462. PubMed ID: 38363015
[TBL] [Abstract][Full Text] [Related]
9. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
bioRxiv; 2022 Aug; ():. PubMed ID: 36032976
[TBL] [Abstract][Full Text] [Related]
10. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
Nature; 2023 Jan; 613(7944):558-564. PubMed ID: 36351451
[TBL] [Abstract][Full Text] [Related]
11. Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system.
Zhou Y; Gammeltoft KA; Ryberg LA; Pham LV; Tjørnelund HD; Binderup A; Duarte Hernandez CR; Fernandez-Antunez C; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
Sci Adv; 2022 Dec; 8(51):eadd7197. PubMed ID: 36542720
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 3CL
Heilmann E; Costacurta F; Moghadasi SA; Ye C; Pavan M; Bassani D; Volland A; Ascher C; Weiss AKH; Bante D; Harris RS; Moro S; Rupp B; Martinez-Sobrido L; von Laer D
Sci Transl Med; 2023 Jan; 15(678):eabq7360. PubMed ID: 36194133
[TBL] [Abstract][Full Text] [Related]
13. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
[TBL] [Abstract][Full Text] [Related]
14. Hotspot residues and resistance mutations in the nirmatrelvir-binding site of SARS-CoV-2 main protease: Design, identification, and correlation with globally circulating viral genomes.
Padhi AK; Tripathi T
Biochem Biophys Res Commun; 2022 Nov; 629():54-60. PubMed ID: 36113178
[TBL] [Abstract][Full Text] [Related]
15. A comprehensive study of SARS-CoV-2 main protease (M
Costacurta F; Dodaro A; Bante D; Schöppe H; Sprenger B; Moghadasi SA; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Kaserer T; Moro S; von Laer D; Heilmann E
bioRxiv; 2023 Oct; ():. PubMed ID: 37808638
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir.
Kiso M; Furusawa Y; Uraki R; Imai M; Yamayoshi S; Kawaoka Y
Nat Commun; 2023 Jul; 14(1):3952. PubMed ID: 37402789
[TBL] [Abstract][Full Text] [Related]
17. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
Ullrich S; Ekanayake KB; Otting G; Nitsche C
Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
[TBL] [Abstract][Full Text] [Related]
18. Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.
Moghadasi SA; Heilmann E; Khalil AM; Nnabuife C; Kearns FL; Ye C; Moraes SN; Costacurta F; Esler MA; Aihara H; von Laer D; Martinez-Sobrido L; Palzkill T; Amaro RE; Harris RS
Sci Adv; 2023 Mar; 9(13):eade8778. PubMed ID: 36989354
[TBL] [Abstract][Full Text] [Related]
19. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
